浙江昂利康制药股份有限公司关于获得化学原料药上市申请批准通知书的公告

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Bupivacaine from the National Medical Products Administration, which will enhance the company's product line and core competitiveness [1][4]. Group 1: Approval Information - The chemical raw material drug approved is Bupivacaine, with registration number Y20230001273 [1]. - The application for the drug was submitted in December 2023, accepted in January 2024, and recently approved [2]. Group 2: Product Application - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [3]. Group 3: Impact on the Company - The approval of Bupivacaine will enrich the company's product line and enhance its core competitiveness [4].